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Dissecting the role of insulin in the complex regula-
tion of triglyceride metabolism is necessary for
understanding dyslipidemia and steatosis. Liver
insulin receptor knockout (LIRKO) mice show that
in the physiological context of feeding, hepatic
insulin signaling is not required for the induction of
mTORC1, an upstream activator of the lipogenic
regulator, SREBP-1c. Feeding induces SREBP-1c
mRNA in LIRKO livers, though not to the extent
observed in controls. A high fructose diet also
partially induces SREBP-1c and lipogenic gene
expression in LIRKO livers. Insulin signaling
becomes more important in the pathological context
of obesity, as knockdown of the insulin receptor in
ob/ob mice, a model of Type 2 diabetes, using anti-
sense oligonucleotides, abolishes the induction of
SREBP-1c and its targets by obesity and ameliorates
steatosis. Thus, insulin-independent signaling path-
ways can partially compensate for insulin in the
induction of SREBP-1c by feeding but the further
induction by obesity/Type 2 diabetes is entirely
dependent upon insulin.
INTRODUCTION
In normal physiology, feeding triggers the release of insulin,
which suppresses glucose production and activates lipogenesis
in the liver. In obesity and Type 2 diabetes, insulin fails to
suppress glucose production, and hence, these conditions are
considered states of insulin resistance. However, lipogenesis is
paradoxically increased. Excessive hepatic lipogenesis
promotes the development of dyslipidemia and atherosclerosis,Cthe leading cause of death in diabetic patients, and the develop-
ment of nonalcoholic fatty liver disease (NAFLD). NAFLD affects
more than 40% of diabetic patients (Williamson et al., 2011), but
effective therapies for it have yet to be found (Cusi, 2009). It has
even been argued that excessive hepatic lipogenesis, by
promoting ectopic lipid deposition in the muscle, could compro-
mise glucose uptake and produce hyperglycemia itself
(McGarry, 1992). Despite the prevalence of obesity and Type 2
diabetes, and the significant morbidity and mortality associated
with these disorders, we have yet to define the factors that drive
hepatic lipogenesis in the insulin resistant state.
At the molecular level, the increase in lipogenesis observed in
insulin-resistant states is due at least in part to dysregulation of
the master transcriptional regulator of lipogenesis, sterol regula-
tory element binding protein (SREBP)-1c. SREBP-1c is capable
of inducing the entire complement of genes necessary for the
synthesis of monounsaturated fatty acids (Horton et al., 1998).
Insulin activates SREBP-1c by at least two mechanisms: it
increases SREBP-1c transcription (Foretz et al., 1999), and it
increases the processing of SREBP-1c from an inactive
membrane-bound precursor to a soluble fragment capable of
translocating to the nucleus to activate transcription (Yabe
et al., 2003). Thus, SREBP-1c is decreased in insulin-deficient
states, such as fasting (Horton et al., 1998) and streptozotocin-
diabetes (Shimomura et al., 1999), but increased in mouse
models of insulin resistance, such asmice fed a high fat diet (Bid-
dinger et al., 2005), ob/obmice (Shimomura et al., 2000), and lip-
odystrophic mice (Shimomura et al., 2000).
There are two possible explanations for the increase in lipo-
genesis observed in the insulin-resistant state. The first possi-
bility is that insulin, despite its inability to control glucose homeo-
stasis, retains its ability to stimulate lipogenesis (Reaven, 1988).
This is conceivable because of the complex nature of insulin
signaling (Biddinger and Kahn, 2006). Upon binding to its
receptor, insulin triggers a branching cascade of signaling
events to exert its myriad effects upon the cell. As suggested
by Brown and Goldstein, the signaling pathways utilized byell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc. 873
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Insulin-Independent Regulation of SREBP-1cinsulin to stimulate SREBP-1c could remain intact in obesity and
Type 2 diabetes, even as the pathways that regulate glucose
metabolism become resistant (Brown and Goldstein, 2008).
Thus, insulin would fail to suppress glucose production, leading
to hyperglycemia and a compensatory hyperinsulinemia. The hy-
perinsulinemia, acting through signaling pathways that remain
sensitive to insulin, would drive SREBP-1c and lipogenesis to
excess.
Alternatively, it is possible that in insulin resistant states, lipo-
genesis is driven by insulin-independent pathways. Particular
attention has recently focused on dietary carbohydrates. The
excessive consumption of carbohydrates, particularly in the
form of sweetened beverages, has risen in parallel with the prev-
alence of obesity, diabetes, and fatty liver disease in our society.
Dietary carbohydrates, particularly fructose, drive lipogenesis
(Mayes, 1993) and excessive fructose intake is correlated with
elevations in serum (Mayes, 1993) and hepatic (Ouyang et al.,
2008) triglyceride levels, as well as obesity and other features
of the metabolic syndrome (Johnson et al., 2007). Whether
carbohydrates increase lipogenesis directly, or indirectly, by
stimulating insulin secretion, has been difficult to dissect.
However, the fact that carbohydrate loads in humans can induce
hypertriglyceridemia even in the presence of somatostatin,
which inhibits insulin secretion, indicates that at least some of
the carbohydrate effect may be independent of insulin signaling
(Ginsberg et al., 1982). Consistent with this, SREBP-1c can be
induced by carbohydrate feeding even in streptozotocin-treated
mice, which are insulin deficient (Matsuzaka et al., 2004). More-
over, SREBP-1c is not the only transcriptional regulator of lipo-
genesis. For example, carbohydrate response element binding
protein (ChREBP) induces lipogenic gene expression primarily
in response to glucose and could potentially contribute to the
insulin-independent regulation of the lipogenic genes (Dene-
chaud et al., 2008).
Using mice with knockdown or knockout of the insulin
receptor, we have dissected the roles of insulin-dependent
versus insulin-independent pathways in the control of SREBP-
1c and hepatic triglycerides under different physiological and
pathological conditions. The livers of liver insulin receptor
knockout (LIRKO) mice are entirely unable to respond to insulin,
due to a lack of the insulin receptor, but are nonetheless
capable of responding to nutrients or other stimuli. We have
previously shown that LIRKO mice have decreased levels of
SREBP-1c and its targets, decreased plasma triglycerides,
and decreased VLDL-triglyceride content (Biddinger et al.,
2008). The fact that humans with insulin receptor mutations
show a similar phenotype, with decreased lipogenesis,
decreased serum triglycerides and decreased VLDL-triglyceride
content, demonstrates the utility of the LIRKO model for
studying the effects of insulin in vivo (Semple et al., 2009). In
the present studies, we show that, surprisingly, insulin signaling
is not required for the control of lipogenic gene expression and
hepatic triglycerides under the normal physiological stimuli of
fasting and feeding. Moreover, lipogenic gene expression is
induced by a fructose diet even in the absence of hepatic insulin
signaling. However, under the pathological conditions of Type 2
diabetes, modeled by ob/ob mice, insulin signaling is required
for the induction of SREBP-1c and the lipogenic genes and
contributes to steatosis.874 Cell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc.RESULTS
Regulation of the Lipogenic Program Is Largely
Preserved in LIRKO Mice under Fasted and Ad Libitum
Fed Conditions
The lipogenic program is under complex control by multiple
factors, including insulin, other hormones, and nutrients them-
selves. In normal physiology, these factors suppress lipogenesis
in the fasted state and activate it in the fed state. To dissect the
specific role of insulin in the control of the lipogenic program, we
used LIRKOmice. LIRKOmice and their littermate controls were
maintained on a standard chow diet and studied after a 24 hr fast
or in the ad libitum fed state.
Relative to their controls, LIRKO mice consumed similar
amounts of food and were of normal weight (Table S1). However,
consistent with the lack of hepatic insulin signaling, LIRKO mice
were hyperglycemic, despite marked hyperinsulinemia, and
were unable to suppress the gluconeogenic enzyme phospho-
enolpyruvate carboxykinase (Pck1) with feeding (Table S1). On
the other hand, the ability of feeding to increase plasma glucose
and thyroid hormone levels, and suppress plasma glucagon
levels, was normal in LIRKO mice, though the suppression of
corticosterone was blunted (Table S1).
In control livers, feeding increased SREBP-1cmRNA levels by
10-fold (Figure 1A). In LIRKO livers, SREBP-1c mRNA levels
were increased 3-fold with feeding, despite their complete
absence of hepatic insulin signaling. The lipogenic genes, acetyl
CoA carboxylase (Acc), fatty acid synthase (Fasn), and stearoyl
CoA desaturase 1 (Scd1), showed a similar expression pattern
with Acc, Fasn, and Scd1 increased 2- to 10-fold in both control
and LIRKO mice (Figures 1B–1D). These data indicate that
though insulin signaling is necessary for maximal induction,
nutrients—either directly, or indirectly, via hormones other than
insulin—are sufficient for the induction of the SREBP-1c and
lipogenic gene transcripts.
ChREBP is another lipogenic transcription factor; it is acti-
vated by glucose (Postic et al., 2004).ChREBPmRNA, in parallel
with blood glucose levels (Table S1), was induced to a similar
level in control and LIRKO mice by feeding (Figure 1E), showing
that the transcriptional regulation of ChREBP is independent of
insulin. However, the activation of ChREBP requires its translo-
cation to the nucleus, which in turn requires the metabolism of
glucose to glucose-6-phosphate by glucokinase, an enzyme
induced by insulin (Dentin et al., 2004). Thus, in control livers,
feeding increased glucokinase expression by 50-fold, and this
was associated with an increase in ChREBP protein in the
nucleus (Figures 1F and 1G). In contrast, feeding induced gluco-
kinase only 3-fold in LIRKO mice. Thus, glucokinase mRNA
levels in the fed state were 50-fold lower than controls, and
LIRKO livers showed no increase in nuclear ChREBP. Conse-
quently, pyruvate kinase (Pklr), a relatively specific target of
ChREBP, was not induced by feeding in LIRKO livers, though it
was induced almost 10-fold in control livers (Figure 1H).
In the fasted state, nonesterified fatty acids are released from
the adipocyte, taken up by the liver, and oxidized to generate
ketones and fuel gluconeogenesis. Plasma nonesterified fatty
acids were similar in control and LIRKO mice in the fasted state
(Figure 1I), and the uptake of free fatty acids was uncompro-
mised in LIRKO hepatocytes (Figure S1A). Direct measurements
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Figure 1. Regulation of Lipogenic Gene Expression and Hepatic Triglycerides by Ad Libitum Feeding Is Largely Preserved in LIRKO Livers
(A–K) LIRKOmice and their littermate controls (CON) were maintained on a chow diet and sacrificed after a 24 hr fast or in the ad libitum fed state. In (A–F) and (H),
hepatic gene expression was measured using real-time PCR. ChREBP and lamin (G) were measured by immunoblotting nuclear extracts (each lane represents
a sample taken from an individual mouse liver). Plasma nonesterified fatty acids (I), hepatic triglycerides (J), and plasma triglycerides (K) were measured at the
time of sacrifice. Error bars represent SEM; n = 4–8; *p < 0.05 versus nonfasted mice of the same genotype; #p < 0.05 versus control mice in the same feeding
state. See also Figure S1 and Table S1.
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Insulin-Independent Regulation of SREBP-1cof fatty acid oxidation in LIRKO hepatocytes in vitro were normal
(Figures S1B and S1C), and the respiratory exchange ratio,
which reflects whole body fatty acid oxidation, was normal
(data not shown). Consistent with this, hepatic triglycerides
were normal in fasted LIRKO livers (Figure 1J).
In the fed state, insulin and other hormones act at the level of
the adipocyte to suppress lipolysis and thereby decrease the flux
of nonesterified fatty acids to the liver. Because insulin receptor
expression is normal in the extrahepatic tissues of the LIRKO
mouse (Figure S2C), the regulation of adipocyte lipolysis would
be expected to be normal. Indeed, in response to feeding, LIRKO
mice, like control mice, showed a 3-fold reduction in plasma
nonesterified fatty acids and a 10-fold reduction in hepatic
triglycerides. Plasma triglycerides were lower in LIRKO mice
than controls, consistent with the decreased triglyceride secre-
tion reported previously (Biddinger et al., 2008), but did not
change with fasting (Figure 1K).
Insulin-Independent Activation of mTORC1 Targets
ThemTORC1 complex is an important regulator of SREBP-1c (Li
et al., 2010; Porstmann et al., 2005; Jeon and Osborne, 2012).
Insulin stimulates mTORC1 via a signaling cascade involvingCAkt. Upon activation, Akt becomes phosphorylated on residues
Thr308 and Ser473 and, in turn, activates mTORC1(Biddinger
and Kahn, 2006).
In fasted control livers, 5 min of insulin stimulation induced
tyrosine phosphorylation of a 100 kDa protein, assumed to be
the insulin receptor, and phosphorylation of Akt on Thr308 and
Ser473 (Figure 2A). In contrast, in LIRKO hepatocytes, insulin
was unable to activate Akt either in vivo or in vitro (Figures 2A
and S2A). However, insulin signaling in LIRKO muscle and fat
was not impaired (Figures S2B and S2C).
Feeding activates mTORC1 in vivo (Sengupta et al., 2010).
Phosphorylation of the ribosomal S6 protein, a well-established
marker of mTORC1 activation, was very low in the livers of
fasted mice of either genotype (Figure 2B). Consistent with
prior reports, 1 hr of feeding robustly induced phospho-S6
levels in control livers (Sengupta et al., 2010). Surprisingly,
feeding was also able to induce phospho-S6 in LIRKO livers,
despite their inability to respond to insulin. This induction was
abolished by the mTORC1 inhibitor, rapamycin (data not
shown).
In addition to stimulating lipogenesis, mTORC1 is required for
the inhibition of ketogenesis upon feeding (Sengupta et al.,ell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc. 875
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Figure 2. Insulin-Independent Activation of
mTORC1
(A) Control and LIRKOmice were fasted overnight,
injected with either vehicle or 3 units of insulin via
the inferior vena cava, and sacrificed 5 min later.
Livers were subjected to immunoblotting.
(B) Mice were fasted for 24 hr, or fasted for 24 hr
and refed a high carbohydrate diet for 1 hr. Livers
were subjected to immunoblotting.
(C–E) Mice were sacrificed in the ad libitum fed
state or after a 24 hr fast. In (C andD), hepatic gene
expressionwasmeasured by real-time PCR. In (E),
ketone levels were measured in the blood at the
time of sacrifice.
(F) Hepatocytes were isolated from 2-month-old
female control and LIRKO mice. After plating,
hepatocytes were incubated overnight in serum-
free medium containing low glucose (5 mM) and
then stimulated for 10 min with high glucose
(25mM), insulin (10 nM), and/or serum (10%). Error
bars represent SEM; n = 4–8; *p < 0.05 versus
nonfasted mice of the same genotype; #p < 0.05
versus control mice in the same feeding state. See
also Figure S2.
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Insulin-Independent Regulation of SREBP-1c2010). Upon feeding, mTORC1 is activated; Cpt1a and Hmgcs2,
two genes required for ketone synthesis, are suppressed, and
blood ketone levels fall. Thus, in the livers of ad libitum fed LIRKO
mice, Cpt1a and Hmgcs2 mRNA levels and blood ketone levels
are decreased 2- to 3-fold relative to the livers of fasted mice
(Figures 2C–2E). Taken together, these data suggest that
mTORC1 activation in response to feeding is intact in LIRKO
livers.
Previous studies have shown that nutrients alone are not suffi-
cient for the activation of mTORC1 and that growth factors must
also be present (Sancak et al., 2008). The insulin and IGF-1
receptors activate an overlapping, if not identical, set of down-
stream targets. Thus, it was conceivable that IGF-1 receptor
could compensate for the lack of insulin receptor in LIRKO hepa-
tocytes. To test this, we measured IGF-1 receptor expression in
LIRKO livers. IGF-1 receptor was undetectable in control livers,
as previously reported (Czech, 1982), as well as LIRKO livers
(Figure S2D). Moreover, hepatocytes cultured from LIRKO livers
failed to respond to IGF-1 (Figure S2A).
Nonetheless, it remained possible that growth factors other
than insulin/IGF-1 could play a permissive role in the activation
of mTORC1 by nutrients in LIRKO hepatocytes. To test this,
primary hepatocytes were isolated from control and LIRKO
livers, and cultured overnight in media containing low glucose
and no serum. Subsequent stimulation of control hepatocytes
with high glucose and insulin produced phosphorylation of the876 Cell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc.mTORC1 target S6 kinase (S6K1) and its
downstream target ribosomal S6 (Fig-
ure 2F). LIRKO hepatocytes failed to
respond to high glucose and insulin.
However, stimulation of LIRKO hepato-
cytes with high glucose and serum, which
contains numerous growth factors in
addition to insulin, induced S6 kinase to
the same level as control hepatocytestreated with high glucose and insulin. Thus, factors in the serum
other than insulin can promote the activation of mTORC1.
Acute Refeeding Fails to Induce Nuclear SREBP-1c
Protein in LIRKO Livers
Refeeding a high carbohydrate diet after fasting is a strong lipo-
genic challenge that is thought to be primarily driven by insulin
and SREBP-1c (Horton et al., 1998). Thus, in contrast to the ad
libitum fed state, the refed state is characterized by an exagger-
ated insulin response, which induces SREBP-1c and lipogenesis
to levels 5-fold greater than those observed in the ad libitum fed
state (Horton et al., 1998). To examine the effects of insulin and
nutrients on SREBP-1c under the stress of refeeding, we
measured SREBP-1c expression in the livers of control and
LIRKO mice fasted for 24 hr, and refed a high carbohydrate
diet for 6–48 hr. In control mice, SREBP-1c mRNA levels
increased within 6 hr of refeeding and reached a plateau by
12 hr (Figure 3A). In LIRKO livers, the same temporal pattern
was observed, but SREBP-1c mRNA levels were induced to
levels only 20% of controls.
SREBP-1c precursor and nuclear protein levels rose in parallel
with mRNA levels in control mice, increasing after 6 hr of refeed-
ing and reaching a plateau by 12 hr (Figure 3B). Precursor levels
of SREBP-1 also increased in LIRKO livers in parallel with mRNA
levels. Despite the increase in precursor SREBP-1, however,
nuclear protein levels remained undetectable, even after 48 hr.
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Figure 3. LIRKO Livers Fail to Accumulate
Nuclear SREBP-1c upon Acute Refeeding
of a High Carbohydrate Diet
(A–H) LIRKO mice and their littermate controls
(CON) were fasted for 24 hr and then refed a high
carbohydrate diet for 6–48 hr. Livers were used to
prepare cDNA for real-time PCR analysis as well
as microsomal and nuclear (Nuc.) extracts.
SREBP-1c mRNA (A) was measured using real-
time PCR. SREBP-1 precursor and nuclear protein
levels (B) were measured by immunoblotting
microsomal and nuclear extracts, respectively.
Calnexin and lamin are shown as loading controls.
Each lane represents extracts prepared from equal
aliquots of liver from three mice. De novo lipo-
genesis (C) was measured as the fraction of newly
synthesized palmitate present 24 hr after refeed-
ing. hepatic triglycerides (D) were measured after
6 hr of refeeding. InsigmRNA (E–G) was measured
using real-time PCR. Insig1 and Insig2 proteins (H)
were measured by immunoblotting microsomal
extracts. Each lane represents extracts prepared
from equal aliquots of liver from three mice. Error
bars represent SEM; n = 4–8; *p < 0.05 versus
control mice. See also Figure S3.
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Insulin-Independent Regulation of SREBP-1cConsistent with this, lipogenesis was markedly lower in refed
LIRKO versus control mice (Figure 3C). Interestingly, however,
hepatic triglyceride levels after 6 hr of refeeding tended to be
increased (Figure 3D), suggesting a lag in the removal of triglyc-
erides from the LIRKO liver, perhaps due to a decrease in triglyc-
eride secretion (Biddinger et al., 2008).
The failure of LIRKO livers to accumulate the nuclear, i.e.,
active, form of SREBP1 upon refeeding suggests that insulin is
necessary for the processing of SREBP-1c. SREBP proteins
are synthesized as inactive, membrane-bound precursor
proteins that become associated with SCAP, the SREBP
cleavage-activating protein (reviewed in Jeon and Osborne
[2012]). Insig proteins reside in the endoplasmic reticulum and
bind to SCAP; in so doing, they retain the SCAP/SREBP complex
in the endoplasmic reticulum and prevent SREBP processing.
When SCAP dissociates from the Insig proteins, the SCAP/
SREBPcomplex can translocate to theGolgi. Twoproteinswhich
reside in theGolgi, Site 1 and Site 2 protease, can then cleave the
SREBP precursor, releasing a soluble fragment that can translo-
cate to the nucleus to activate transcription. There are two InsigCell Metabolism 15, 873–proteins. Insig1 is thought to mediate
feedback inhibition of the SREBPs, as
Insig1 transcription is driven by the
SREBP proteins (Engelking et al., 2004).
Insig2 is encoded by two transcripts.
Insig2a is the major Insig transcript in the
fasted liver. It is induced by fasting and
streptozotocin treatment and suppressed
by feeding and insulin treatment (Yabe
et al., 2003). Insig2b is a ubiquitous tran-
script (Yabe et al., 2003).
LIRKO livers showed normal mRNA
levels of SCAP, Site 1 and Site 2 protease
(Figure S3A), but marked derangementsin Insig expression. In control livers, the increase in nuclear
SREBP-1 observed with refeeding was associated with an
increase in Insig1 mRNA and protein (Figures 3E and 3H). In
LIRKO livers, the failure to induce nuclear SREBP-1c was asso-
ciated with a failure to induce Insig1 mRNA and protein.
Insig2a mRNA decreased with refeeding in control mice, as
expected (Figure 3F). Despite the lack of insulin signaling,
Insig2a mRNA fell to an even greater extent with refeeding in
LIRKO livers. Insig2bmRNA levels were relatively stable with re-
feeding in both control and LIRKO livers, though the expression
in LIRKO livers was increased (Figure 3G). Insig2 protein was
also higher in LIRKO versus control livers (Figure 3H).
Using an adenovirus encoding shRNA against Insig2, we
knocked down Insig2 in the livers of nonfasted LIRKO mice (Fig-
ure S3B). Compared with LIRKO mice injected with an adeno-
virus encoding a scrambled shRNA sequence, LIRKO mice in-
jected with shInsig2 adenovirus showed very low levels of
Insig2, indicating the virus was effective. Though there was slight
trend for the shInsig2 adenovirus to increase nuclear levels of
SREBP-1 in LIRKO livers, it was not to the level observed in884, June 6, 2012 ª2012 Elsevier Inc. 877
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Figure 4. Mice with Knockdown of the
Insulin Receptor Fail to Accumulate Nuclear
SREBP-1c upon Acute Refeeding of a High
Carbohydrate Diet
(A–K) Two-month-old mice homozygous for the
floxed allele of the insulin receptor were injected
with adenovirus encoding GFP or Cre re-
combinase and studied 2 to 3 weeks later. Mice
were fasted for 24 hr and refed a high carbohy-
drate diet for 6 hr prior to sacrifice. Liver lysates (A)
were subjected to immunoblotting with antibodies
against the insulin receptor. Body weight (B) was
measured at the time of sacrifice. Triglycerides (C)
were measured in plasma taken after a 4 hr fast.
Glucose tolerance testing (D) was performed by
fasting mice overnight and then injecting them
with 1 g/kg glucose, intraperitoneally. In (E, F, H,
and I), RT PCR was used to measure hepatic gene
expression. SREBP-1 protein (G) wasmeasured in
nuclear extracts (prepared from equal amounts of
liver taken from at least three mice per group).
Plasma (J) and hepatic triglycerides (K) measured
in the refed state, at the time of sacrifice, are
shown. Error bars represent SEM; n = 3–5, *p <
0.05 versus mice injected with adenovirus en-
coding GFP. See also Figure S4.
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Insulin-Independent Regulation of SREBP-1cthe livers of their littermate controls. Thus, the failure of LIRKO
livers to accumulate nuclear SREBP-1c is due to increased In-
sig2 protein as well as other factors.
Acute Refeeding Fails to Induce Nuclear SREBP-1c
Protein in Mice with Knockdown of the Insulin Receptor
Because LIRKO mice lack hepatic insulin signaling from birth, it
is conceivable that some of their phenotype is due to develop-
mental defects or other chronic compensatory changes. There-
fore, we knocked down the insulin receptor in 2- to 3-month-old
control mice, homozygous for the floxed allele of the insulin
receptor, using adenoviral mediated expression of Cre recombi-
nase (AdCre). AdCre mice showed a very similar phenotype to
LIRKOmice. Compared tomice infected with adenovirus encod-
ing green fluorescent protein (AdGFP), AdCre treated mice
showed a 90% decrease in hepatic insulin receptor protein,
normal body weights, and a 50% decrease in fasting plasma
triglycerides (Figures 4A–4C). AdCre-treated mice also showed
fasting hypoglycemia, presumably due to limited glycogen878 Cell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc.reserves, and hyperglycemia after the
injection of glucose (Figure 4D).
The response of AdCre treated mice to
refeeding was almost identical to that of
LIRKO mice. Thus, AdCre and AdGFP
treated mice were fasted for 24 hr and
refed for 6 hr with a high carbohydrate
diet. Relative to AdGFP treated mice,
AdCre-treated mice showed increased
Pck1 mRNA (Figure 4E) and a 75%
decrease in SREBP-1c mRNA. The
other SREBP isoforms, SREBP-1a and
SREBP-2, were decreased 30%–40% in
AdCre-treated mice (Figure 4F). LikeLIRKO livers, the livers of AdCre treated mice showed markedly
reduced nuclear SREBP-1, despite decreased Insig1 mRNA,
and a 60%–80% reduction in Fasn and Scd1(Figures 4G–4I).
Neither AdCre (Figure 4H) nor LIRKO (Figure 3F) mice at the
6 hr refeeding time point showed significant changes in Insig2a
mRNA. Finally, AdCre-treated mice in the refed state showed
a trend toward reduced plasma triglycerides and increased
hepatic triglycerides (Figures 4J and 4K).
High Fructose Feeding Increases Lipogenic Gene
Expression in LIRKO Mice
Dietary fructose is a strong stimulus for lipogenesis. Catalytic
amounts of fructose activate glucokinase posttranscriptionally
by promoting its dissociation from the glucokinase regulatory
protein (Doiron et al., 1994; Mayes, 1993; Petersen et al.,
2001). Fructose could therefore be particularly important in the
insulin-independent induction of lipogenesis. Thus, LIRKO
mice and their controls were subjected to a high fructose (60%
fructose) versus standard chow diet for one week. In control
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Figure 5. Effects of Fructose Feeding on LIRKO Livers
(A–L) LIRKOmice and their littermate controls (CON) were placed on either a chow (C, Chow) or high fructose diet (F, 60% fructose byweight) for 1 week andwere
sacrificed in the nonfasted state. Livers were analyzed for gene expression and triglyceride content. In (A, C, and D) and (F–I), gene expression was measured by
real-time PCR. SREBP-1 (B) and ChREBP (E) proteins were measured by immunoblotting nuclear extracts. Acc, Fasn, and Scd1 (J) were measured by
immunoblotting liver lysates. Plasma (K) and hepatic triglycerides (L) were measured at the time of sacrifice. Error bars represent SEM; n = 4–8, *p < 0.05 versus
chow-fed mice of the same genotype; #p < 0.05 versus control mice on the same diet; equal amounts of liver from three mice were pooled to prepare samples for
immunoblotting SREBP-1, Acc, Fasn, and Scd1; for ChREBP immunoblot, each lane represents an individual mouse liver. See also Figure S5.
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Insulin-Independent Regulation of SREBP-1cmice, the high fructose diet produced a 75% increase in Srebp-
1cmRNA and an increase in nuclear SREBP-1c (Figures 5A and
5B). In LIRKOmice, fructose feeding produced a 3-fold increase
in Srebp-1cmRNA and amodest increase in nuclear SREBP-1c.
Importantly, the levels of nuclear SREBP-1 protein in fructose-
fed LIRKO livers were markedly lower than those found in even
chow-fed controls, indicating the dominant role played by insulin
in the accumulation of nuclear SREBP-1.
In control livers, ChREBP mRNA was not induced by fructose
feeding, and glucokinase was increased more than 2-fold; no
consistent change in ChREBP nuclear protein was observed
(Figures 5C–5E). In LIRKO livers, neither ChREBP nor glucoki-
nasemRNAwas induced by fructose feeding. Nonetheless, fruc-
tose markedly increased the amount of nuclear ChREBP in
LIRKO livers. In parallel, pyruvate kinase was increased by
3-fold in LIRKO livers upon fructose feeding (Figure 5F).
The induction of nuclear SREBP-1 in control livers and
ChREBP in LIRKO livers was associated with an increase in lipo-
genic gene expression (Figures 5G–5I). In control mice, Scd1
was increased 20-fold, and Acc, Fasn, and pyruvate kinaseCwere increased 5- to 10-fold with fructose feeding. In LIRKO
livers, Scd1, Acc, Fasn, and pyruvate kinase increased 3- to
10-fold with fructose feeding.
In parallel, fructose feeding increased the protein levels of
Scd1, Acc and Fasn in both control and LIRKO mice (Figure 5J).
Though lipogenic expression at the mRNA and protein levels
were consistently lower in the LIRKO livers on either diet, fruc-
tose feeding induced lipogenic gene expression in fructose
fed-LIRKO mice to levels similar to or higher than those found
in control mice on the chow diet. This indicates the ability of
a high fructose diet to drive lipogenic gene expression even in
the complete absence of hepatic insulin signaling.
Plasma triglyceride levels were not significantly changed by
the high fructose diet in either control or LIRKOmice (Figure 5K).
Hepatic triglycerides were increased 3-fold in control mice sub-
jected to the fructose diet (Figure 5L). In contrast, LIRKO mice
showed no change in hepatic triglycerides despite the increase
in lipogenic gene expression. These data indicate that insulin is
also necessary for some other aspect of triglyceride metabolism
required for steatosis.ell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc. 879
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Figure 6. The Induction of Lipogenic Gene
Expression in ob/ob Mice Requires Insulin
Signaling
(A–I) Five- to six-week-old male ob/ob mice and
their lean controls (WT) were treated with chemi-
cally modified antisense oligonucleotides (ASO)
for 4 weeks and sacrificed in the nonfasted state.
Insulin receptor expression (A) was measured by
immunoblotting liver lysates. Blood glucose levels
(B) were measured after a 4 hr fast. Plasma insulin
(C) and body weights (D) were measured at the
time of sacrifice. Livers (E–G) were analyzed for
gene expression using real-time PCR. Plasma
triglycerides (H) were measured after a 4 hr fast.
Livers (I) were subjected to hematoxylin and eosin
staining. Error bars represent SEM; n = 3–6;
*p < 0.05 versus WT mice treated with the
same ASO; #p < 0.05 versus mice of the same
genotype treated with control ASO. See also
Figures S6 and S7.
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Insulin-Independent Regulation of SREBP-1cThe acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes,
which are encoded by two genes, catalyze the committed step in
triglyceride biosynthesis and are important for the development
of steatosis (Yen et al., 2008). Interestingly, LIRKO mice showed
decreased levels of DGAT2mRNA, which could contribute to the
failure of LIRKO livers to accumulate hepatic triglycerides on the
fructose diet (Figure S5B). However, DGAT1 mRNA (Figure S5A)
and DGAT activity (Figure S5C) were normal in LIRKO livers.
IR ASO Therapy in ob/ob Mice
In Type 2 diabetes, plasma insulin levels rise as the b-cells of the
pancreas attempt to maintain glucose homeostasis. This
increase in insulin levels could potentially drive SREBP-1c and
the lipogenic genes. To test this directly, we used ob/ob mice.
In these mice, leptin deficiency leads to hyperphagia, obesity
and severe hyperinsulinemia. To block the effects of hyperinsu-
linemia on the liver, we knocked out the insulin receptor using
chemically modified antisense oligonucleotides.
Wild-type and ob/obmice on the C57BL/6J background were
treated with an antisense oligonucleotide against the insulin880 Cell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc.receptor (IR ASO) or a control antisense
oligonucleotide (CON ASO). Treatment
with the IR ASO reduced liver insulin
receptor protein to near undetectable
levels (Figure 6A). There was also
a decrease in insulin receptor content in
the adipose tissue, but this did not signif-
icantly alter phosphorylation or expres-
sion of hormone sensitive lipase, expres-
sion of adipocyte triglyceride lipase,
plasma nonesterified free fatty acids or
plasma adiponectin (Figures S6A–S6D).
In mice treated with the CON ASO, lep-
tin deficiency produced hyperglycemia,
raising fasting blood glucose levels from
136 mg/dl to 347 mg/dl (Figure 6B). In
mice treated with the IR ASO, the effect
was exacerbated, as fasting bloodglucose levels increased from 127 to 519 mg/dl, though Pck1
gene expression was not significantly changed (Figure S6E).
Leptin deficiency produced hyperinsulinemia during treatment
with either the CON or IR ASO, even though the livers of
mice treated with the IR ASO were unable to respond to the
hyperinsulinemia (Figure 6C). Consistent with the worsening of
diabetes, ob/ob mice treated with the IR ASO accumulated
less weight than ob/ob mice treated with the control ASO
(Figure 6D).
In the presence of the control ASO, leptin deficiency produced
a 40% increase in SREBP-1c (Figure 6E), a 5-fold induction in
Fasn (Figure 6F), and an 8-fold induction in Scd1 (Figure 6G).
However, in the presence of the IR ASO, these effects were
entirely abolished, and the expression of SREBP-1c, Fasn, and
Scd1 was similar in wild-type and ob/ob mice. Even the ability
of leptin deficiency to induce glucokinase, ChREBP, and pyru-
vate kinase was abolished by treatment with the IR ASO (Figures
S6G–S6I). Consequently, in the presence of the CONASO, leptin
deficiency produced severe hepatic steatosis; in the presence of
the IR ASO, the steatosis was markedly attenuated (Figure 6I).
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Figure 7. Interaction between Insulin-
Dependent and Insulin-Independent
Signaling Pathways in the Control of
SREBP-1c and Hepatic Triglycerides
There are multiple nodes at which insulin-depen-
dent and -independent signaling pathways can
crosstalk in the regulation of SREBP-1c and
hepatic triglycerides. Hepatic insulin signaling
independent pathways involve the direct effects of
nutrients, other hormones, and other tissues.
These pathways are able to activate mTORC1 and
increase SREBP-1cmRNA. In the case of fructose,
they are also able to activate ChREBP. Moreover,
insulin and other hormones, acting on the adipo-
cyte, can regulate the flux of nonesterified fatty
acids to the liver. Insulin-dependent signaling
pathways are required for the processing of
SREBP-1c, maximal lipogenic gene expression,
and the induction of steatosis. The relative roles
played by the insulin-dependent and insulin-inde-
pendent signaling pathways vary in different
physiological and pathophysiological states.
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Insulin-Independent Regulation of SREBP-1cThe ability of leptin deficiency to increase plasma triglycerides,
however, remained intact (Figure 6H).
Another commonly used mouse model of Type 2 diabetes is
diet-induced obesity (DIO). To determine whether the ablation
of hepatic insulin signaling had similar effects in DIO mice,
control and LIRKO mice were fed a high fat diet for 18 weeks.
On the high fat diet, body weight and fat mass were similar in
control and LIRKO mice, but LIRKO mice were more glucose
intolerant (Figures S7A–S7C). LIRKOmice also showed reduced
levels of nuclear SREBP-1, lipogenic gene expression, and
hepatic triglycerides (Figures S7D–S7G). Similarly, the injection
of AdCre into DIO mice homozygous for the floxed allele of the
insulin receptor also worsened glucose tolerance, but lowered
nuclear SREBP-1c, lipogenic gene expression, and plasma
triglycerides and tended to lower hepatic triglycerides (Fig-
ure S4). Thus, the interruption of hepatic insulin signaling is suffi-
cient to lower SREBP-1c and its targets in both the ob/ob and
DIO models of Type 2 diabetes.
DISCUSSION
Insulin is one of several factors regulating SREBP-1c and hepatic
triglyceridemetabolism (Figure 7). Our data, together with data in
mice with liver-specific knockout of both IRS-1 and IRS-2 (Guo
et al., 2009), or Akt2 (Leavens et al., 2009), show that feeding
is able to activate mTORC1 and induce SREBP-1c mRNA via
insulin-independent signaling pathways. The activation of
ChREBP and lipogenic gene expression by fructose is also inde-
pendent of hepatic insulin signaling, as is the regulation of
nonesterified fatty acid flux from the adipocyte, an important
driver of hepatic triglycerides. Hepatic insulin signaling is,
however, required for the accumulation of nuclear SREBP-1cCell Metabolism 15, 873–protein. Since SREBP-1c activates its
own transcription, completing a feed-
forward loop (Chen et al., 2004; Dif
et al., 2006), insulin is also necessary for
the full induction of SREBP-1c mRNA.These insulin-dependent signaling pathways are critical for the
pathological induction of SREBP-1c and lipogenic gene expres-
sion observed in obesity.
One important regulator of SREBP-1c is Insig2a. In vitro, insulin
increases degradation of the Insig2a transcript (Yellaturu et al.,
2009), but it may also increase Insig2a transcription, since activa-
tion of Liver X Receptor, a nuclear receptor that is induced by
insulin, increases Insig2a mRNA (Hegarty et al., 2005). Our data
add further complexity. First, Insig2a expression in vivo can be
suppressed independently of hepatic insulin signaling, as Insig2a
mRNA levels are decreased in the livers of refed LIRKOmice (Fig-
ure 3F), AdCre-treated mice on the high fat diet (Figure S4F), and
mice treated with IR ASO (Figure S6K). Such in vivo regulation by
feeding could be mediated by a factor other than insulin. One
intriguing possibility is that in vivo Insig2a is suppressed by leptin,
as Insig2a mRNA is increased by leptin deficiency (Kammoun
et al., 2009), even after knockdown of the insulin receptor by
ASO treatment (Figure S6K). Second, insulin may regulate Insig2
posttranscriptionally, as Insig2 protein is increased in LIRKO
livers despite lower levels of Insig2a mRNA. Moreover, insulin is
required for other aspects of SREBP-1c processing, nuclear
import or stability, as knockdown of Insig2 does not fully restore
nuclear SREBP-1c protein in LIRKO livers (Figure S3B).
Insulin signaling plays a key role in the induction of SREBP-1c
and the lipogenic genes by obesity/Type 2 diabetes. That is,
though feeding induces mRNA levels of SREBP-1c and its
targets via insulin-independent signaling pathways, the further
induction which occurs in obesity is entirely insulin dependent.
Neither leptin deficiency, nor any of the other metabolic or
hormonal changes associated with the Type 2 diabetic state is
capable of inducing lipogenic gene expression in the absence
of hepatic insulin signaling. This is consistent with concept of884, June 6, 2012 ª2012 Elsevier Inc. 881
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Insulin-Independent Regulation of SREBP-1c‘‘selective insulin resistance.’’ Although the specific signaling
pathways that remain sensitive to insulin in obesity remain
unclear, continued insulin signaling through phosphatidylinositol
3-kinase (Anai et al., 1999) and its downstream targets mTORC1
(Um et al., 2004; Khamzina et al., 2005), as well as PKC-l (Stand-
aert et al., 2004), have been reported.
Both mTORC1-dependent and -independent signals are
necessary for the full activation of SREBP-1c (Yecies et al.,
2011; Wan et al., 2011). We therefore propose amodel of obesity
in which over-nutrition, independently of insulin, drives
mTORC1, while insulin signaling through a distinct pathway,
such as PKC-l, permits the accumulation of nuclear SREBP-1c
and activation of its feed-forward transcriptional loop. However,
our data do not rule out the possibility that insulin, in the setting
of hyperinsulinemia and obesity, becomes an important driver
of mTORC1, even though it is not required for the induction of
mTORC1 by feeding.
Fructose can bypass the requirement for insulin in the regula-
tion of the lipogenic genes, as the fructose diet increases Acc,
Fasn, and Scd1mRNA and protein in LIRKO livers to levels equal
to or higher than those found in chow-fed controls. This is due, in
part, to activation of ChREBP, as nuclear ChREBP levels and
expression of theChREBP target, pyruvate kinase, are increased
in the livers of fructose-fed LIRKO mice. The activation of
ChREBP requires glucokinase, which in turn requires insulin for
its transcription (Dentin et al., 2004). However, fructose, which
activates glucokinase posttranscriptionally by promoting its
translocation from the nucleus to the cytosol, could drive
ChREBP independently of insulin (Doiron et al., 1994; Mayes,
1993; Petersen et al., 2001).
In human Type 2 diabetes, hyperinsulinemia, dietary fructose,
and other lipogenic stimuli are present. Our data suggest that
identifying and targeting the specific signaling pathways by
which insulin stimulates lipogenesis, aswell as decreasing dietary
fructose, could be extremely effective in reducing SREBP-1c and
ameliorating hepatic steatosis in Type 2 diabetes.
EXPERIMENTAL PROCEDURES
A detailed description of the Experimental Procedures can be found in the
Supplemental Information.
Animals, Diets, and Treatments
Generation and genotyping of LIRKO (Cre+/, IR lox/lox) mice and their litter-
mate controls (Cre/, IR lox/lox) has been described previously (Michael
et al., 2000). LIRKO mice were maintained on a mixed genetic background.
Unless otherwise indicated, the mice used in these experiments were male,
eight to ten weeks of age, and sacrificed at 2 p.m. For fasting and refeeding
studies, mice were sacrificed under the following conditions: ad libitum fed;
after a 24 hr fast; or after a 24 hr fast followed by refeeding a high carbohy-
drate diet (TD. 88122, Harlan Teklad Diets). For adenoviral-mediated knock-
down of the insulin receptor, 2-month-old mice homozygous for the floxed
allele of the insulin receptor were injected via tail vein with 5 3 109 pfu of
adenovirus encoding Cre or GFP (Viraquest), and sacrificed 21 days later.
For the fructose feeding experiments, mice were fed ad libitum with a 60%
fructose diet for 1 week (TD. 00202, Harlan Teklad Diets). For the antisense
oligonucleotide-mediated knockdown of the insulin receptor, C57BL/6J
mice and ob/ob mice (Jackson Labs) were given 50 mg/kg IP of the chemi-
cally modified ASO each week for 4 weeks and sacrificed 1 day after the final
dose. All animal experiments were performed with the approval of the Institu-
tional Animal Care and Research Advisory Committee at Children’s Hospital
Boston.882 Cell Metabolism 15, 873–884, June 6, 2012 ª2012 Elsevier Inc.Gene Expression Analysis
Gene expressionwasmeasured using real-time PCR. Results were normalized
to the housekeeping gene, Tbp, and the value of the control groupwas set to 1.
Western Blotting
Microsomal and nuclear protein extracts for measurements of SREBP-1
(Horton et al., 1998), microsomal extracts for the measurements of the Insig
proteins (Engelking et al., 2004), and nuclear extracts for the measurements
of ChREBP (Miao et al., 2009) were prepared as previously described, and
subjected to western blotting.
Phenotypic and Histological Characterization
Blood glucose and ketone levels were measured using a glucometer and
ketone meter. Plasma insulin (ALPCO) was measured using a commercial
kit. Plasma measurements of nonesterified fatty acids (Wako Chemicals)
and total triglycerides (ThermoScientific) were made using colorimetric
assays. Hepatic triglycerides were measured as previously described (Bid-
dinger et al., 2008). Hematoxylin and eosin staining of the liver was performed
by the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core.
De Novo Lipogenesis
Mice were fasted for 24 hr, refed a high carbohydrate diet for 24 hr, and then
sacrificed. One hour prior to refeeding, mice were injected IP with 24 ml/g body
weight of deuterated normal saline, and their drinking water was replaced with
4%D2O. The fraction of newly synthesized palmitate wasmeasured using gas
chromatography-electron impact ionization mass spectrometry as previously
described (Leavens et al., 2009).
Primary Hepatocytes
Primary hepatocytes were isolated from 8-to 10-week-old female control and
LIRKO mice as previously described (Biddinger et al., 2008). After plating the
hepatocytes, they were cultured overnight in DMEM (5 mM glucose), without
serum or insulin. They were then stimulated for 10 min with DMEM (5 or
25 mM glucose), with or without 10 nM insulin, or 10% fetal bovine serum.
Statistics
Differences between groups were assessed by Student’s t test using the
Bonferroni correction for multiple testing. Bars and error bars correspond to
the mean and SEM, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.05.002.
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